STRIDE's Efficacy and Safety in Asian Hepatocellular Carcinoma

We would like to offer some constructive feedback on the recent publication, "Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma" (1). While the study provides promising data on the use of the STRIDE regimen in the Asian subgroup of hepatocellular carcinoma (HCC) patients, we believe that certain aspects of the results interpretation and discussion merit further exploration to provide a more comprehensive understanding of the findings.